论文部分内容阅读
目的:观察拉米夫定单用与联合α干扰素治疗慢性乙型肝炎的疗效。方法:慢性乙肝64例,单用拉米夫定34例,100 mg/d,联合α干扰素治疗组30例,皮下注α干扰素5 MU/d,连续14 d后,改为5 MU,1周3次,同时口服拉米夫定100 mg/d,疗程6个月停用干扰素,随后单用拉米夫定18个月。结果:两组ALT复常率、HBV-DNA转换率无明显差异(P>0.05),联合治疗组的HBeAg/抗-HBe血清转换率高于单用拉米夫定组(P<0.05),联合治疗组的YMDD变异率低于单用拉米夫定组(P<0.05)。结论:联合治疗2 a疗效优于单用拉米夫定,能提高血清转换率。减少病毒YMDD变异。
Objective: To observe the curative effect of lamivudine alone and combined with interferon-alpha on chronic hepatitis B Methods: Sixty-four patients with chronic hepatitis B, 34 patients with lamivudine alone, 100 mg / d combined with interferon-alpha (IFN-α), 30 patients were given subcutaneous IFN-α 5 MU / d for 14 days, 3 times a week, at the same time oral lamivudine 100 mg / d, treatment for 6 months to disable interferon, followed by lamivudine alone 18 months. Results: The ALT normalization rate and HBV-DNA conversion rate showed no significant difference between the two groups (P> 0.05). The seroconversion rate of HBeAg / anti-HBe in combined therapy group was higher than that of lamivudine alone group (P <0.05) The YMDD mutation rate in the combined treatment group was lower than that in the lamivudine alone group (P <0.05). Conclusion: Combination therapy 2 a curative effect is superior to lamivudine alone, can improve the seroconversion rate. Reduce virus YMDD mutation.